Join Mayer Brown FDA Regulatory partner George O’Brien and Global Investigations & White Collar Defense partner Arun G. Rao for 2025’s first installment of our FDA Lifecycle Management webinar series. In this webinar, Arun and George will discuss the impact on FDA and FDA-regulated companies of the new Trump administration, including the newly-confirmed Secretary of HHS and the nominee for FDA Commissioner.
This seminar will leverage George’s experience counseling FDA-regulated companies, as well as Arun’s experience at the Department of Justice’s Consumer Protection Branch, where he oversaw criminal and civil enforcement actions, including fraud and consumer protection matters involving the FDA. Combining these two perspectives, George and Arun will discuss the regulatory and enforcement implications of a rapidly evolving landscape at FDA under the new administration, including:
- Shifting priorities across all agency programs, including food, drugs and biologics, medical devices, and cosmetics;
- Potential impact of staffing loss on enforcement and product reviews;
- The Trump Executive Orders regarding deregulation;
- Drug pricing and the Inflation Reduction Act;
- Potential impact of tariffs on drug and biotech development; and
- Likely areas where regulated industry can expect greater continuity.
United States
1:00 p.m. – 2:00 p.m. EDT
12:00 p.m. – 1:00 p.m. CDT
11:00 a.m. – 12:00 p.m. MDT
10:00 a.m. – 11:00 a.m. PDT
Europe
6:00 p.m. – 7:00 p.m. BST
7:00 p.m. – 8:00 p.m. CEST
CLE credit is pending.
For additional information, please contact Alayne Thomas at athomas@mayerbrown.com or +1 312 701 7529.
